SSY Group Ltd
HKEX:2005
Net Margin
SSY Group Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| HK |
S
|
SSY Group Ltd
HKEX:2005
|
10.2B HKD |
18%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
775.3B USD |
24%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
373.9B USD |
16%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
228.6B CHF |
20%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
174.1B GBP |
13%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
196B CHF |
23%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
219.3B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
167.6B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
140B USD |
13%
|
SSY Group Ltd
Glance View
SSY Group Ltd. stands out as a significant player in the Chinese pharmaceutical industry, seamlessly interweaving its intricate supply chain operations with its robust manufacturing capabilities. Founded in 1994, the company has its roots in the scenic Hebei Province and has evolved into a powerful force in the realm of injectable pharmaceuticals and oral solutions. The organization primarily operates through its core segment—manufacturing and distributing intravenous infusion solutions. By leveraging cutting-edge technology and adhering to stringent quality standards, SSY Group has managed to capture a sizable share of the domestic market, ensuring a steady stream of revenue. The firm's prowess isn't limited to its pharmaceutical expertise. SSY Group's growth strategy involves a careful blend of organic expansion and strategic acquisitions, which enables it to broaden its product categories and penetrate new regional markets. By offering a wide variety of products ranging from antibiotics to anti-infection drugs, the company adeptly meets diverse healthcare needs while simultaneously driving profitability. Additionally, SSY Group bolsters its financial performance through its involvement in both research and development. By dedicating resources toward innovation, it aspires to maintain its competitive edge, producing high-value products that facilitate sustainable long-term growth. Thus, SSY Group's tightly-knit approach to blending manufacturing excellence with strategic growth initiatives paints a picture of a company adeptly navigating the challenges and opportunities of the healthcare sector.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on SSY Group Ltd's most recent financial statements, the company has Net Margin of 18.4%.
You don't have any saved screeners yet